Showing 8751-8760 of 20877 results for "".
IBD Care Reimagined: Personalized, Proactive, and Target-Driven Management
https://reachmd.com/programs/cme/ibd-care-reimagined-personalized-proactive-and-target-driven-management/54174/Explore IBD treatment selection in this comprehensive program for community gastroenterologists, with topics including therapies, targets, and emerging data.Treatment Intensification in HSPC: From Risk Stratification to Precision Medicine
https://reachmd.com/programs/cme/Treatment-Intensification-in-HSPC-From-Risk-Stratification-to-Precision-Medicine/56689/Explore individualized treatment intensification, molecular profiling, and adverse event management in metastatic hormone-sensitive prostate cancer.Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
https://reachmd.com/programs/cme/chairpersons-perspective-evidence-informed-clinical-decision-making-in-her2-overexpressed-and-trop2-targeted-nsclc/39894/Study HER2 IHC testing, efficacy, and NCCN guidance supporting ADC sequencing for HER2-overexpressed NSCLC and TROP2-directed ADCs for EGFR-TKI–resistant NSCLC.Diagnosing and Treating IBS: It Begins With One Simple Question
https://reachmd.com/programs/cme/diagnosing-and-treating-ibs-it-begins-with-one-simple-question/36607/Diagnosing and Treating IBS: It Begins With One Simple QuestionOptimizing IgAN Care: Sparsentan’s Role Amid the Latest KDIGO Guideline Updates
https://reachmd.com/clinical-practice/nephrology/optimizing-igan-care-sparsentans-role-amid-the-latest-kdigo-guideline-updates/30044/Examine updated KDIGO 2025 IgAN guidelines and sparsentan’s role in managing proteinuria and slowing kidney function decline.Closing the Gaps: Global Implementation of Lipid Guidelines
https://reachmd.com/programs/cme/gaps-global-implementation-lipid-guidelines/54672/A new modular CME-accredited program designed to support clinicians in translating evolving lipid guidelines into everyday practice. Delivered as a 60-minute webcast, divided into chapters for convenience, it integrates U.S. and international perspectives and focuses on equitable cardiovascular careDESTINY-Breast05: Additional Data From the Interim Analysis
https://reachmd.com/clinical-practice/oncology-hematology/destiny-breast05-additional-data-from-the-interim-analysis/49126/Check out the interim DESTINY-Breast05 analysis of T-DXd showing improved IDFS and manageable safety vs T-DM1 in high-risk HER2+ BC with residual disease.Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
https://reachmd.com/programs/cme/clinical-implications-of-emerging-data-on-b7-h3directed-adcs-in-the-future-of-es-sclc/39979/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Practical Dermatology Roundtable: The Role of Adjuvant Skin Cleansing and Moisturizing in Treating Psoriasis and Other Inflammatory Diseases, Ch. 2
https://reachmd.com/programs/the-practical-dermatology-roundtable/practical-dermatology-roundtable-the-role-of-adjuvant-skin-cleansing-and-moisturizing-in-treating-psoriasis-and-other-inflammatory-diseases-ch-2/56870/In the second installment of a nine-part series, host Ted Lain, MD, MBA, FAAD, and guests Zoe Diana Draelos, MD, and Firas George Hougeir, MD, FAAD, review the study design, including patient selection, treatment regimens, and objective and subjective assessment methods used to evaluate outcomes.1Future-Proofing in HAE: Advances in Long-term Prophylaxis to Prevent Attacks and Improve Quality of Life
https://reachmd.com/programs/cme/future-proofing-in-hae-advances-in-long-term-prophylaxis-to-prevent-attacks-and-improve-quality-of-life/54448/On-demand webcast with expert faculty presentation on addressing the unmet needs and optimizing treatment for hereditary angioedema (HAE), including long-term prophylaxis therapy, for patients with HAE.